Please login to the form below

Not currently logged in
Email:
Password:

brigatinib

This page shows the latest brigatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Meanwhile another new entrant - Alunbrig (brigatinib) from Takeda - is also making headway after its first approval in 2017, making $13m by the end of the calendar year.

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... Takeda. Company acquisition. Oncology

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics